Welcome to our dedicated page for NKGen Biotech news (Ticker: NKGN), a resource for investors and traders seeking the latest updates and insights on NKGen Biotech stock.
NKGen Biotech Inc (NKGN) is a clinical-stage biotechnology company advancing natural killer cell therapies for cancer and neurodegenerative diseases. This page serves as the definitive source for official updates on clinical trials, regulatory developments, and research breakthroughs.
Investors and researchers will find timely announcements about NKGen's pipeline progress, including its lead candidates SNK02 and troculeucel. The curated news collection covers critical milestones: clinical data readouts, partnership agreements, manufacturing advancements, and scientific presentations validating NK cell therapy efficacy.
All content is sourced directly from company releases and verified industry publications. Regular updates ensure stakeholders maintain current awareness of NKGen's work in non-genetically modified NK cell platforms and their applications across oncology and neurological conditions.
Bookmark this page for structured access to NKGN's evolving story in immunotherapy. Check back frequently for developments that could impact both patient care and investment perspectives in cutting-edge biotherapeutics.
NKGen Biotech announced that its cryopreserved, enhanced natural killer cell therapy, SNK01, has been cleared to progress into Phase 2 clinical trials for moderate Alzheimer’s disease. The therapy showed clinical benefit and no drug-related adverse events in Phase 1. The Phase 2 trial will involve 30 patients, with 20 receiving SNK01 and 10 receiving a placebo, and will begin in Q2 2024. This trial aims to assess the therapy's efficacy and safety over a full year. Preliminary results are promising, with improvements in cognitive function and daily activities observed.
NKGen Biotech, a clinical-stage biotech company, will present its autologous NK cell therapy, SNK01, at the 5th International Cell & Gene Therapy China Summit. SNK01, which shows enhanced cytotoxicity and receptor expression, targets neurodegenerative diseases and solid tumors. CEO Paul Y. Song will discuss manufacturing advances and results combining SNK01 with immune checkpoint inhibitors and Erbitux for resistant cancers. The presentation, set for May 23, 2024, will also highlight SNK01's potential against multiple neurodegenerative diseases by improving key protein levels.
NKGen Biotech, Inc. (NKGN) received FDA clearance for its SNK01 NK cell therapy in Parkinson's disease, advancing its neurodegenerative disease program. The Phase 1/2a clinical trial is set to commence in 2H 2024, with SNK01 showing promising potential in addressing Parkinson's disease through enhanced cytotoxicity and activating receptor expression.
FAQ
What is the current stock price of NKGen Biotech (NKGN)?
What is the market cap of NKGen Biotech (NKGN)?
